euglena Co., Ltd. AI Stock Analysis
Want to see JP:2931 full AI Analyst Report?
euglena Co., Ltd. (2931) AI Stock Analysis
euglena Co., Ltd.
(TSE/TYO:2931)
The score is driven primarily by improving financial performance (notably stronger operating results and cash flow in 2024–2025), but is held back by continued net losses and negative ROE. Technicals are notably weak with the price below key moving averages and bearish momentum indicators, while valuation is constrained by a negative P/E and a low dividend yield.
euglena Co., Ltd. (2931) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 43.80B
- Dividend Yield
- 0.62%
- Average Volume (3M)
- 670.12K
- Price to Earnings (P/E)
- -256.3
- Beta (1Y)
- 0.51
- Revenue Growth
- 7.72%
- EPS Growth
- -1053.09%
- Country
- Japan
- Employees
- 793
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
euglena Co., Ltd. Business Overview & Revenue Model
Company Description
Euglena Co., Ltd. is a Japanese enterprise specializing in the research, development, cultivation, and marketing of microalgae. Its operations are structured around two primary divisions: Healthcare Business and Energy/Environment Business. The compa...
How the Company Makes Money
The company makes money primarily by selling microalgae-derived products and ingredients. Key revenue streams include: (1) Consumer product sales in the health/functional food domain, where Euglena-branded supplements, health foods, and related consu...
euglena Co., Ltd. Financial Statement Overview
Summary
Strong multi-year revenue expansion and a sharp operating recovery (operating profit turning positive in 2024 and improving in 2025) with consistently high gross margins. However, net income remains negative and returns on equity are still below zero, keeping the score moderate.
Income Statement
46NeutralBalance Sheet
50NeutralCash Flow
63Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.32B | 50.37B | 47.62B | 46.48B | 44.39B | 27.54B |
| Gross Profit | 35.78B | 32.06B | 30.00B | 29.81B | 29.05B | 16.22B |
| EBITDA | 6.67B | 6.47B | 3.90B | 1.51B | -359.00M | -3.50B |
| Net Income | -172.00M | -805.00M | -650.00M | -2.65B | -2.67B | -4.03B |
Balance Sheet | ||||||
| Total Assets | 69.27B | 72.33B | 73.26B | 59.62B | 57.27B | 61.01B |
| Cash, Cash Equivalents and Short-Term Investments | 17.17B | 21.16B | 20.63B | 15.79B | 9.95B | 10.19B |
| Total Debt | 23.06B | 27.68B | 25.92B | 25.07B | 22.22B | 24.91B |
| Total Liabilities | 37.70B | 43.80B | 41.14B | 39.40B | 37.92B | 40.42B |
| Stockholders Equity | 33.18B | 30.96B | 31.70B | 20.21B | 19.35B | 20.58B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 4.98B | 2.23B | 345.00M | 595.00M | 1.18B |
| Operating Cash Flow | 0 | 5.19B | 2.65B | 658.00M | 924.00M | 1.38B |
| Investing Cash Flow | 0 | -585.00M | -7.99B | -646.00M | 1.23B | -10.34B |
| Financing Cash Flow | 0 | -2.43B | -485.00M | 5.83B | -2.99B | 12.06B |
euglena Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2931, the sentiment is Neutral. The current price of 323.00 is below the 20-day moving average (MA) of 323.65, below the 50-day MA of 335.04, and below the 200-day MA of 362.59, indicating a bearish trend. The MACD of -5.82 indicates Negative momentum. The RSI at 48.20 is Neutral, neither overbought nor oversold. The STOCH value of 42.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2931.
euglena Co., Ltd. Peers Comparison
Overall Rating
JP:445272.6Outperform
JP:491167.8Neutral
JP:492267Neutral
JP:452765Neutral
JP:496761Neutral
JP:293148Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | JPY 3.66T | 26.20 | 12.88% | 1.92% | 6.31% | 18.40% | |
| 68Neutral | JPY 1.67T | 35.12 | ― | 1.19% | 5.79% | ― | |
| 67Neutral | JPY 351.83B | 27.61 | 4.51% | 2.27% | 4.49% | 70.29% | |
| 65Neutral | JPY 599.90B | 17.64 | 10.90% | 1.93% | 7.39% | -7.02% | |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 61Neutral | JPY 524.70B | 114.70 | 2.19% | 1.48% | 2.46% | -60.25% | |
| 48Neutral | JPY 45.06B | -256.35 | ― | 0.62% | 7.72% | -1053.09% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2931 | euglena Co., Ltd. | 323.00 | -98.00 | -23.28% | |
| JP:4452 | Kao Corp | 4046.00 | 843.95 | 26.36% | |
| JP:4967 | Kobayashi Pharmaceutical Co | 7075.00 | 1880.58 | 36.20% | |
| JP:4922 | Kose Corporation | 6167.00 | 1286.11 | 26.35% | |
| JP:4527 | Rohto Pharmaceutical Co | 2584.00 | 180.49 | 7.51% | |
| JP:4911 | Shiseido Company,Limited | 4191.00 | 1884.70 | 81.72% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
